PIK3CA and breast cancer: In this study, the combination of low-dose metronomic VRL and alpelisib revealed a significant reduction of cell viability and proliferation with synergistic anti-tumor effects in HR-positive, HER2-negative, PIK3CA-mutated BC cell lines.